Pay in 4 interest-free payments of $7.05 Learn more
Ships within 48 hours · Estimated delivery Aug 15 - Aug 20
While semaglutide did not reduce incident COVID-19, among participants who developed COVID-19, those who were treated with semaglutide had fewer COVID-19-related adverse events or died from COVID-19
Clinical evidence: A 2025 randomized clinical trial (published in JAMA Network Open ) found that low-dose semaglutide reduced the amount of alcohol consumed during a laboratory drinking task, lowered peak breath alcohol levels, and significantly reduced weekly alcohol craving in adults with alcohol use disorder
M., Bodzin, J
These side effects are generally mild to moderate and tend to diminish over time as the body adjusts to the medication
It also supports better blood sugar control in individuals with type 2 diabetes
1 illustrates the study selection process
